retatrutide clinical trial results 2024 Medscape | Retatrutide, Eli Lilly's first-in-class triple hormone receptor agonist, delivered meaningful weight loss at 80 weeks in all doses in the retatrutide type 2 diabetes phase
Pay in 4 interest-free payments of $5.02 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30











:max_bytes(150000):strip_icc():focal(748x241:750x243)/Serena-Williams-1-012726-2698f17c5ab647929a79194c436d85ea.jpg)









